The “metabolic memory” theory and the early treatment of hyperglycemia in prevention of diabetic complications

Nutrients

Volumn 9, Issue 5, 2017, Pages

  Roberto, Testa ^a   Rita, Bonfigli Anna ^a   Prattichizzo, Francesco ^b   La Sala, Lucia ^b   De Nigris, Valeria ^c   Ceriello, Antonio ^b,c,d  

^a INRCA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Diabetic complications; Metabolic memory; Type 2 diabetes mellitus

Indexed keywords

METFORMIN; PIOGLITAZONE;

BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; GENE EXPRESSION; GLYCEMIC CONTROL; HISTONE MODIFICATION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; OXIDATIVE STRESS; REVIEW;

EID: 85018446154     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu9050437     Document Type: Review

References (65)

1. Nathan, D.M., Cleary, P.A., Backlund, J.Y., Genuth, S.M., Lachin, J.M., Orchard, T.J., Raskin, P., Zinman, B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005, 353, 2643-2653.
2. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N. Engl. J. Med. 2003, 348, 2294-2303.
3. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 2008, 359, 1565-1576.
4. Engerman, R.L., Kern, T.S. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987, 36, 808-812.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329, 977-986.
6. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287, 2563-2569.
7. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003, 290, 2159-2167.
8. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, de Boer, I.H., Sun, W., Cleary, P.A., Lachin, J.M., Molitch, M.E., Steffes, M.W., Zinman, B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N. Engl. J. Med. 2011, 365, 2366-2376.
9. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A. 10-Year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008, 359, 1577-1589.
10. Gaede, P., Lund-Andersen, H., Parving, H.H., Pedersen, O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008, 358, 580-591.
11. Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P.D., Zieve, F.J., Marks, J., Davis, S.N., Hayward, R., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009, 360, 129-139.
12. Reaven, P.D., Moritz, T.E., Schwenke, D.C., Anderson, R.J., Criqui, M., Detrano, R., Emanuele, N., Kayshap, M., Marks, J., Mudaliar, S., et al. Intensive glucose-lowering therapy reduces cardiovascular disease events in Veterans Affairs Diabetes Trial participants with lower calcified coronary atherosclerosis. Diabetes 2009, 58, 2642-2648.
13. Ceriello, A. The emerging challenge in diabetes: The “metabolic memory”. Vasc. Pharmacol. 2012, 57, 133-138.
14. Russell, N.D., Cooper, M.E. 50 years forward: Mechanisms of hyperglycaemia driven diabetic complications. Diabetologia 2015, 58, 1708-1714.
15. Roy, S., Sala, R., Cagliero, E., Lorenzi, M. Overexpression of fibronectin induced by diabetes or high glucose: Phenomenon with a memory. Proc. Natl. Acad. Sci. USA 1990, 87, 404-408.
16. Engerman, R., Bloodworth, J.M., Jr., Nelson, S. Relationship of microvascular disease in diabetes to metabolic control. Diabetes 1977, 26, 760-769.
17. Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M., Beebe, D., Oates, P., Hammes, H.P., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404, 787-790.
18. Kowluru, R.A., Kanwar, M., Kennedy, A. Metabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries. Exp. Diabetes Res. 2007, 2007, 21976.
19. Kowluru, R.A., Abbas, S.N., Odenbach, S. Reversal of hyperglycemia and diabetic nephropathy: Effect of reinstitution of good metabolic control on oxidative stress in the kidney of diabetic rats. J. Diabetes Complicat. 2004, 18, 282-288.
20. Esper, R.J., Nordaby, R.A., Vilariño, J.O., Paragano, A., Cacharrón, J.L., Machado, R.A. Endothelial dysfunction: A comprehensive appraisal. Cardiovasc. Diabetol. 2006, 5, 4.
21. Ceriello, A., Esposito, K., Ihnat, M., Thorpe, J., Giugliano, D. Long-term glycemic control influences the long-lasting effect of hyperglycemia on endothelial function in type 1 diabetes. J. Clin. Endocrinol. Metab. 2009, 94, 2751-2756.
22. Ceriello, A., Esposito, K., Ihnat, M., Thorpe, J., Giugliano, D. Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in type 1 diabetic patients with different characteristics. Diabet. Med. 2010, 27, 911-917.
23. Ceriello, A., Ihnat, M.A. ‘Glycaemic variability’: A new therapeutic challenge in diabetes and the critical care setting. Diabet. Med. 2010, 27, 862-867.
24. Schisano, B., Tripathi, G., McGee, K., McTernan, P.G., Ceriello, A. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia 2011, 54, 1219-1226.
25. Pugliese, G. Do advanced glycation end products contribute to the development of long-term diabetic complications? Nutr. Metab. Cardiovasc. Dis. 2008, 18, 457-460.
26. Stirban, A., Tschoepe, D., Stratmann, B. Shifting the disease management paradigm from glucose. What are the pros? Diabetes Care 2009, 32, S349-S352.
27. Giacco, F., Brownlee, M. Oxidative stress and diabetic complications. Circ. Res. 2010, 107, 1058-1070.
28. Ceriello, A., Inhat, M.A., Thorpe, J.E. The “metabolic memory”: Is more than just tight glucose control necessary to prevent diabetic complications? J. Clin. Endocrinol. Metab. 2009, 94, 410-415.
29. Jax, T.W. Metabolic memory: A vascular perspective. Cardiovasc. Diabetol. 2010, 9, 51.
30. Reddy, M.A., Zhang, E., Natarajan, R. Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia 2015, 58, 443-455.
31. Reddy, M.A., Natarajan, R. Epigenetic mechanisms in diabetic vascular complications. Cardiovasc. Res. 2011, 90, 421-429.
32. Pirola, L., Balcerczyk, A., Okabe, J., El-Osta, A. Epigenetic phenomena linked to diabetic complications. Nat. Rev. Endocrinol. 2010, 6, 665-675.
33. Wegner, M., Neddermann, D., Piorunska-Stolzmann, M., Jagodzinski, P.P. Role of epigenetic mechanisms in the development of chronic complications of diabetes. Diabetes Res. Clin. Pract. 2014, 105, 164-175.
34. Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E.K., Calkin, A.C., Brownlee, M., Cooper, M.E., El-Osta, A. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene activating epigenetic marks that coexist on the lysine tail. Diabetes 2009, 58, 1229-1236.
35. Miao, F., Gonzalo, I.G., Lanting, L., Natarajan, R. In vivo chromatin remodelling events leading to inflammatory gene transcription under diabetic conditions. J. Biol. Chem. 2004, 279, 18091-18097.
36. Reddy, M.A., Natarajan, R. Role of epigenetic mechanisms in the vascular complications of diabetes. Subcell. Biochem. 2013, 61, 435-454.
37. Al-Haddad, R., Karnib, N., Assaad, R.A., Bilen, Y., Emmanuel, N., Ghanem, A., Younes, J., Zibara, V., Stephan, J.S., Sleiman, S.F. Epigenetic changes in diabetes. Neurosci. Lett. 2016, 625, 64-69.
38. Baek, D., Villén, J., Shin, C., Camargo, F.D., Gygi, S.P., Bartel, D.P. The impact of microRNAs on protein output. Nature 2008, 455, 64-71.
39. Iorio, M.V., Piovan, C., Croce, C.M. Interplay between microRNAs and the epigenetic machinery: An intricate network. Biochim. Biophys. Acta 2010, 1799, 694-701.
40. Breving, K., Esquela-Kerscher, A. The complexities of microRNA regulation: Mirandering around the rules. Int. J. Biochem. Cell Biol. 2010, 42, 1316-1329.
41. Guay, C., Regazzi, R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat. Rev. Endocrinol. 2013, 9, 513-521.
42. McClelland, A.D., Kantharidis, P. MicroRNA in the development of diabetic complications. Clin. Sci. 2014, 126, 95-110.
43. Beltrami, C., Angelini, T.G., Emanueli, C. Noncoding RNAs in diabetes vascular complications. J. Mol. Cell. Cardiol. 2015, 89, 42-50.
44. Thompson, J.A., Webb, R.C. Potential role of Toll-like receptors in programming of vascular dysfunction. Clin. Sci. 2013, 125, 19-25.
45. Guarner, V., Rubio-Ruiz, M.E. Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease. Interdiscip. Top. Gerontol. 2015, 40, 99-106.
46. Goldin, A., Beckman, J.A., Schmidt, A.M., Creager, M.A. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 2006, 114, 597-605.
47. Ceriello, A., Hanefeld, M., Leiter, L., Monnier, L., Moses, A., Owens, D., Tajima, N., Tuomilehto, J. Postprandial glucose regulation and diabetic complications. Arch. Intern. Med. 2004, 164, 2090-2095.
48. Ceriello, A. Postprandial hyperglycemia and diabetes complications: Is it time to treat? Diabetes 2005, 54, 1-7.
49. Ceriello, A., Quagliaro, L., Piconi, L., Assaloni, R., Da Ros, R., Maier, A., Esposito, K., Giugliano, D. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004, 53, 701-710.
50. Ahmed, N., Babaei-Jadidi, R., Howell, S.K., Thornalley, P.J., Beisswenger, P.J. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care 2005, 28, 2465-2471.
51. Schiekofer, S., Andrassy, M., Chen, J., Rudofsky, G., Schneider, J., Wendt, T., Stefan, N., Humpert, P., Fritsche, A., Stumvoll, M., et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 2003, 52, 621-633.
52. Rahbar, S., Natarajan, R., Yerneni, K., Scott, S., Gonzales, N., Nadler, J.L. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. Acta 2000, 301, 65-77.
53. Miyata, T., van Ypersele, D.S., Ueda, Y., Ichimori, K., Inagi, R., Onogi, H., Ishikawa, N., Nangaku, M., Kurokawa, K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J. Am. Soc. Nephrol. 2002, 13, 2478-2487.
54. Yoshida, T., Yamagishi, S., Nakamura, K., Matsui, T., Imaizumi, T., Takeuchi, M., Koga, H., Ueno, T., Sata, M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator activated receptor-gamma activation. Diabetologia 2006, 49, 3094-3099.
55. Corgnali, M., Piconi, L., Ihnat, M., Ceriello, A. Evaluation of gliclazide ability to attenuate the hyperglycaemic ‘memory’ induced by high glucose in isolated human endothelial cells. Diabetes Metab. Res. Rev. 2008, 24, 301-319.
56. Swislocki, A.L., Jialal, I. Glucagon-like peptide-1 receptor agonists and diabetic cardiovascular disease: Implications of the LEADER study. Metab. Syndr. Relat. Disord. 2016, 14, 375-377.
57. Geyer, P.E., Wewer Albrechtsen, N.J., Tyanova, S., Grassl, N., Iepsen, E.W., Lundgren, J., Madsbad, S., Holst, J.J., Torekov, S.S., Mann, M. Proteomics reveals the effects of sustained weight loss on the human plasma proteome. Mol. Syst. Biol. 2016, 12, 901.
58. Kuwata, H., Iwasaki, M., Shimizu, S., Minami, K., Maeda, H., Seino, S., Nakada, K., Nosaka, C., Murotani, K., Kurose, T., et al. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: A randomised, controlled crossover, exploratory trial. Diabetologia 2016, 59, 453-461.
59. Wu, T., Little, T.J., Bound, M.J., Borg, M., Zhang, X., Deacon, C.F., Horowitz, M., Jones, K.L., Rayner, C.K. A protein preload enhances the glucose-lowering efficacy of vildagliptin in type 2 diabetes. Diabetes Care 2016, 39, 511-517.
60. Li, Q.R., Wang, Z., Zhou, W., Fan, S.R., Ma, R., Xue, L., Yang, L., Li, Y.S., Tan, H.L., Shao, Q.H., et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway. Neural Regen. Res. 2016, 11, 345-351.
61. Janssen, H.L., Reesink, H.W., Lawitz, E.J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A.J., Patick, A.K., Chen, A., Zhou, Y., et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368, 1685-1694.
62. Dávalos, A., Chroni, A. Antisense oligonucleotides, microRNAs, and antibodies. Handb. Exp. Pharmacol. 2015, 224, 649-689.
63. Santulli, G., Wronska, A., Uryu, K., Diacovo, T.G., Gao, M., Marx, S.O., Kitajewski, J., Chilton, J.M., Akat, K.M., Tuschl, T., et al. A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J. Clin. Investig. 2014, 124, 4102-4114.
64. Hartig, S.M., Hamilton, M.P., Bader, D.A., McGuire, S.E. The miRNA interactome in metabolic homeostasis. Trends Endocrinol. Metab. 2015, 26, 733-745.
65. Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., Stoffel, M. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005, 438, 685-689.